Dapagliflozin exhibits more than 1200-fold higher potency against human SGLT2 compared with SGLT1, and its effects on T2D have been investigated in preclinical [133,134] and clinical practices [135,136,137,138,139,140,141,142]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.